Most recently he was Executive Vice President Discovery at Proteros, where his responsibilities included new company building. Tarig studied biology at the University of Würzburg and the State University of New York at Albany. He earned his PhD at the German Cancer Research Center (DKFZ) in Heidelberg and conducted his postdoctoral training at the New York University School of Medicine.

Prior to this, he held clinical positions of increasing responsibility at AstraZeneca, GSK, Novartis and ADC Therapeutics.

At ADC Therapeutics, Jens oversaw all aspects of clinical development of several successful programs, including loncastuximab teserine (Zynlonta). Before that, he was Lead Clinical Program Leader at Novartis, where he was responsible for progressing small molecule compounds and a monoclonal antibody through multiple clinical trials. Jens is an author of numerous publications and serves as visiting senior lecturer at King’s College London, Faculty of Life Sciences & Medicine. He is board-certified in Medical Microbiology and Virology (Germany) as well as Pharmaceutical Medicine (UK). Jens holds an MD and a PhD from the University of Hamburg and completed a postdoctoral fellowship at the Laboratory of Cell Regulation & Carcinogenesis, National Cancer Institute, National Institutes of Health in Bethesda, Maryland.

Collaborating with esteemed academic centers, biotechnology, and pharma partners, he has driven the exploration of new target classes, and shaped innovative clinical development directions through fundamental translational research. Frank studied biology at the Ruhr University of Bochum and Heinrich Heine University of Düsseldorf where he received his diploma and PhD degrees. He carried out his postdoctoral training at The Scripps Research Institute in La Jolla, California.